Daklinza daclatasvir: Phase II data

The open-label, Chinese Phase II SODAPI trial in 26 non-cirrhotic patients with chronic HCV genotype 1b infection showed that Harvoni ledipasvir/sofosbuvir plus Sunvepra asunaprevir (Group 1, n=12), Sovaldi sofosbuvir plus Daklinza daclatasvir and Olysio simeprevir

Read the full 353 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE